Published: 2019-05-24

Reno-protective effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers in type 2 diabetic nephropathy with elevated urine albumin to creatinine ratio

Ashok Vankayala, Karuna Sagar Mantha, Praveen Varma B. H. V. K., Suresh Babu Sayana, Raju D. S. S. K.


Background: Nephropathy is responsible for an End Stage Renal Disease (ESRD) in type 2 diabetics if uncontrolled. The monotherapy/combination of Angiotensin Converting Enzyme inhibitor (ACEi) and Angiotensin II Receptor Blockers (ARBs) can retard the progression of urine albumin to creatinine ratio in diabetic nephropathy but, the data shows an inconsistency in the efficacy of these drugs. So, the present study was aimed at comparing the reno-protective effect of ACEi/ARBs in type 2 diabetics.

Methods: A prospective, randomized study is conducted at Maharaja’s Institute of Medical Sciences, Nellimarla, Vizianagaram, Andhra Pradesh, India with 100 patients, who are randomly categorised and equally distributed among the two groups and treated with Enalapril (ACEi) and Losartan (ARBs) for 6 months. 24-hour urine albumin to creatinine ratio and HbA1c are recorded before and after the treatment.

Results: Enalapril and losartan showed a non-significant reduction in urine albumin to creatinine ratio from 196.2±17.5 to 185.9±15.2 (p=0.66) and 236.8±16.3 to 193.7±20.6 (p=0.11) respectively. A strict glycemic control has shown a reduction in HbA1c in both the groups.

Conclusions: Present findings suggested that losartan is relatively more effective than enalapril in reducing the 24-hour urine albumin to creatinine ratio of diabetic nephropathy patients. Along with these drugs, regulation of blood glucose will assist in retarding the progression of nephropathy in type 2 diabetics.


Angiotensin converting enzyme inhibitor, Angiotensin II receptor blockers, Diabetic nephropathy, End stage renal disease

Full Text:



Yesudian CA, Grepstad M, Visintin E, Ferrario A. The economic burden of diabetes in India: a review of the literature. Globalization Heal. 2014;10(1):80.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diab Care. 2004;27(5):1047-53.

Lim AK. Diabetic nephropathy-complications and treatment. Int J Nephrol Renovascul Dis. 2014;7:361.

Satirapoj B, Adler SG. Prevalence and management of diabetic nephropathy in western countries. Kidney Dis. 2015;1(1):61-70.

Lim CT, Nordin NZ, Fadhlina NZ, Anim MS, Kalaiselvam T, Haikal WZ, et al. Rapid decline of renal function in patients with type 2 diabetes with heavy proteinuria: a report of three cases. BMC Nephrol. 2019;20(1):22.

Ghaderian SB, Hayati F, Shayanpour S, Mousavi SS. Diabetes and end-stage renal disease; a review article on new concepts. J Renal Injury Prevention. 2015;4(2):28.

Shahbazian H, Rezaii I. Diabetic kidney disease; review of the current knowledge. J Renal Injury Prevention. 2013;2(2):73.

Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. New Eng J Med. 2004;351(19):1941-51.

Phoon RK. Chronic kidney disease in the elderly: assessment and management. Aus Fam Physician. 2012;41(12):940.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Reno-protective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Eng J Med. 2001;345(12):851-60.

Tai C, Gan T, Zou L, Sun Y, Zhang Y, Chen W, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovascul Dis. 2017;17(1):257.

Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kid Blood Press Res. 2018;43:768-779.

Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. New Eng J Med. 2013;369(20):1892-903.

Karami A, Baradaran A. Comparative evaluation of three different methods for HbA1c measurement with High-performance liquid chromatography in diabetic patients. Adv Biomed Res. 2014;3.

Sung KC, Ryu S, Lee JY, Lee SH, Cheong E, Hyun YY, et al. Urine albumin/creatinine ratio below 30 mg/g is a predictor of incident hypertension and cardiovascular mortality. J Am Heart Assoc. 201;5(9):e003245.

Hsu FY, Lin FJ, Od HT, Huarg SH, Wang CC. Reno-protective effect of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic patients with proteinuria. Kid Blood Press Res. 2017;42:358-368.

Rüster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006;17(11):2985-91.

Vivian E, Mannebach C. Therapeutic approaches to slowing the progression of diabetic nephropathy–is less best?. Drugs Context. 2013;2013:212249.